| References: |
Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment.
in vitro: Entacapone inhibits catechol-O-methyltransferase(COMT) with similar IC50 in different tissues including live, duodenum, kidney and lung, but entacapone is more active than tolcapone in those tissues. Entacapone (< 100 μM) is a potent inhibitor of α-syn and β-amyloid (Aβ) oligomerization and fibrillogenesis, and also protects against extracellular toxicity induced by the aggregation of both proteins in PC12 cells.
in vivo: Levodopa/carbidopa/entacapone has been shown to improve the pharmacokinetic profile of levodopa and provide superior symptomatic control compared with conventional levodopa/dopa decarboxylase inhibitor therapy. We report four case histories describing clinical experience of using levodopa/carbidopa/entacapone 200/50/200 mg, one of the latest doses of this formulation, in a range of patients with Parkinson's disease. These cases illustrate that levodopa/carbidopa/entacapone 200/50/200 mg provides improvements in symptomatic control. For the detailed information of Entacapone, the solubility of Entacapone in water, the solubility of Entacapone in DMSO, the solubility of Entacapone in PBS buffer, the animal experiment (test) of Entacapone, the cell expriment (test) of Entacapone, the in vivo, in vitro and clinical trial test of Entacapone, the EC50, IC50,and affinity,of Entacapone, For the detailed information of Entacapone, the solubility of Entacapone in water, the solubility of Entacapone in DMSO, the solubility of Entacapone in PBS buffer, the animal experiment (test) of Entacapone, the cell expriment (test) of Entacapone, the in vivo, in vitro and clinical trial test of Entacapone, the EC50, IC50,and affinity,of Entacapone, Please contact DC Chemicals. |
